801 Factors associated with SLE flares after HCQ taper, discontinuation or maintenance in the SLICC inception cohort: lower education linked with higher flare risk

Abstract

was unaffected by the absence of plasminogen activator inhibitor1 or tissue plasminogen activator, suggesting that protection is related to the action of Serp-1 on macrophage function. Conclusions Serp-1 blocks pristane-induced lung hemorrhage by enhancing LXR-regulated M2 macrophage polarization and Klf4-regulated IL-10 production. In view of the similarities between DAH in pristane-treated mice and SLE patients, clinical trials of Serp-1 for DAH in SLE may be warranted. Since Serp-1 treatment increases expression of the reverse cholesterol transporter ABCA1, it also may have beneficial effects on atherosclerosis in SLE patients. Supporting the feasibility of future clinical studies in SLE, Serp-1 treatment reduced myocardial damage in patients with acute coronary syndrome. Acknowledgments This work was supported by NIH grant R01-AR44731. We are grateful to Dr. Alexandra Lucas (Arizona State University) for providing recombinant Serp-1 protein.